Title:
NOVEL IMMUNOSUPPRESSIVE INTERLEUKIN 2
Document Type and Number:
WIPO Patent Application WO/2020/130300
Kind Code:
A1
Abstract:
The present invention relates to an interleukin 2 analogue, which has altered binding affinity for interleukin 2 alpha receptor and interleukin 2 beta receptor, compared to the wild type.
More Like This:
Inventors:
OH EUH LIM (KR)
LEE HYO RAN (KR)
KIM JIN YOUNG (KR)
HEO YONG HO (KR)
LEE HYO RAN (KR)
KIM JIN YOUNG (KR)
HEO YONG HO (KR)
Application Number:
PCT/KR2019/012716
Publication Date:
June 25, 2020
Filing Date:
September 30, 2019
Export Citation:
Assignee:
HANMI PHARM IND CO LTD (KR)
International Classes:
C07K14/55
Domestic Patent References:
| WO2018089420A1 | 2018-05-17 | |||
| WO2017220989A1 | 2017-12-28 |
Foreign References:
| KR20130118363A | 2013-10-29 | |||
| KR20170070091A | 2017-06-21 |
Other References:
WEIGEL, U. ET AL.: "Mutant proteins of human interleukin 2. Renaturation yield, proliferative activity and receptor binding", EUR. J. BIOCHEM, vol. 180, no. 2, 1989, pages 295 - 300, XP055443620, DOI: 10.1111/j.1432-1033.1989.tb14647.x
HEATON K. M. ET AL.: "Human interleukin 2 analogues that preferentially bind the intermediate-affinity interleukin 2 receptor lead to reduced secondary cytokine secretion: implications for the use of these interleukin 2 analogues in cancer immunotherapy", CANCER RES., vol. 53, no. 11, 1993, pages 2597 - 2602, XP001205311
See also references of EP 3901167A4
HEATON K. M. ET AL.: "Human interleukin 2 analogues that preferentially bind the intermediate-affinity interleukin 2 receptor lead to reduced secondary cytokine secretion: implications for the use of these interleukin 2 analogues in cancer immunotherapy", CANCER RES., vol. 53, no. 11, 1993, pages 2597 - 2602, XP001205311
See also references of EP 3901167A4
Attorney, Agent or Firm:
SON, Min (KR)
Download PDF: